Duration of Antimicrobial Treatment for Bacteremia in Canadian Critically Ill Patients∗

Critical Care Medicine

Volumn 44, Issue 2, 2016, Pages 256-264

  Daneman, Nick ^a   Rishu, Asgar H ^a   Xiong, Wei ^a   Bagshaw, Sean M ^b   Dodek, Peter ^c   Hall, Richard ^d   Kumar, Anand ^e   Lamontagne, Francois ^f   Lauzier, Francois ^g   Marshall, John ^h   Martin, Claudio M ⁱ   McIntyre, Lauralyn ^j   Muscedere, John ^k   Reynolds, Steve ^c   Stelfox, Henry T ^l   Cook, Deborah J ^m   Fowler, Robert A ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^g LAVAL UNIVERSITY   (Canada)

^h ST MICHAEL'S HOSPITAL   (Canada)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^j UNIVERSITY OF OTTAWA   (Canada)

^k QUEEN S UNIVERSITY   (Canada)

^l UNIVERSITY OF CALGARY   (Canada)

^m MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

Antibacterial treatment; Bacteremia; Bloodstream infection; Critical care; Intensive care; Mortality

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; CANADA; CANADIAN; COAGULASE NEGATIVE STAPHYLOCOCCUS; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DEATH; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT DURATION; URINARY TRACT; AGE; AGED; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG ADMINISTRATION; IMMUNOCOMPROMISED PATIENT; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY;

AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CANADA; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84954319036     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001393     Document Type: Article

References (40)

1. Vincent JL, Bihari DJ, Suter PM, The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995 274 639 644
2. Renaud B, Brun-Buisson C, ICU-Bacteremia Study Group Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med 2001 163 1584 1590
3. Gholami K, Parsa S, Shalviri G, Anti-infectives-induced adverse drug reactions in hospitalized patients. Pharmacoepidemiol Drug Saf 2005 14 501 506
4. Stevens V, Dumyati G, Fine LS, Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011 53 42 48
5. Dodek PM, Norena M, Ayas NT, Length of stay and mortality due to Clostridium difficile infection acquired in the intensive care unit. J Crit Care 2013 28 335 340
6. Neuhauser MM, Weinstein RA, Rydman R, Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 2003 289 885 888
7. Aarts MA, Brun-Buisson C, Cook DJ, Antibiotic management of suspected nosocomial ICU-acquired infection: Does prolonged empiric therapy improve outcome? Intensive Care Med 2007 33 1369 1378
8. Hepburn MJ, Dooley DP, Skidmore PJ, Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004 164 1669 1674
9. Sandberg T, Skoog G, Hermansson AB, Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: A randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet 2012 380 484 490
10. el Moussaoui R, de Borgie CA, van den Broek P, Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: Randomised, double blind study. BMJ 2006 332 1355
11. Chastre J, Wolff M, Fagon JY, PneumA Trial Group Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003 290 2588 2598
12. Havey TC, Fowler RA, Daneman N, Duration of antibiotic therapy for bacteremia: A systematic review and meta-analysis. Crit Care 2011 15 R267
13. Daneman N, Shore K, Pinto R, Antibiotic treatment duration for bloodstream infections in critically ill patients: A national survey of Canadian infectious diseases and critical care specialists. Int J Antimicrob Agents 2011 38 480 485
14. Leaf DA, Neighbor WE, Schaad D, A comparison of self-report and chart audit in studying resident physician assessment of cardiac risk factors. J Gen Intern Med 1995 10 194 198
15. Baumann BM, Cline DM, Cienki JJ, Provider self-report and practice: Reassessment and referral of emergency department patients with elevated blood pressure. Am J Hypertens 2009 22 604 610
16. Montaño DE, Phillips WR, Cancer screening by primary care physicians: A comparison of rates obtained from physician self-report, patient survey, and chart audit. Am J Public Health 1995 85 795 800
17. Clinical and Laboratory Standards Institute Principles and Procedures for Blood Cutlures; Approved Guideline M47-A 2011
18. Baddour LM, Wilson WR, Bayer AS, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications: A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America. Circulation 2005 111 e394 e434
19. Zimmerli W, Clinical practice. Vertebral osteomyelitis. N Engl J Med 2010 362 1022 1029
20. Zimmerli W, Trampuz A, Ochsner PE, Prosthetic-joint infections. N Engl J Med 2004 351 1645 1654
21. Solomkin JS, Mazuski JE, Bradley JS, Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010 50 133 164
22. de Smet AM, Kluytmans JA, Blok HE, Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: An open-label, clustered group-randomised, crossover study. Lancet Infect Dis 2011 11 372 380
23. Rishu A, Marinoff N, Wang J, Determining inter-rater reliability in documenting potential source of bacteremia in critically ill patients. Abstr ATS Meeting May 2014 San Diego
24. American Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005 171 388 416
25. Horan TC, Andrus M, Dudeck MA, CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008 36 309 332
26. Craig J, Daneman N, Rishu A, Measuring the duration of adequate antimicrobial treatment in critical care. Abstr 2013 Toronto, Ontario, Canada Canadian Critical Care Forum
27. Austin PC, Mamdani MM, Stukel TA, The use of the propensity score for estimating treatment effects: Administrative versus clinical data. Stat Med 2005 24 1563 1578
28. Austin PC, Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011 10 150 161
29. Agresti A, Min Y, Effects and non-effects of paired identical observations in comparing proportions with binary matched-pairs data. Stat Med 2004 23 65 75
30. Havey TC, Fowler RA, Pinto R, Duration of antibiotic therapy for critically ill patients with bloodstream infections: A retrospective cohort study. Can J Infect Dis Med Microbiol 2013 24 129 137
31. Desu MM, Raghavarao D, Sample Size Methodology 1990 New York, NY Academic Press
32. Machin D, Campbell M, Fayers P, Sample Size Tables for Clinical Studies 1997 Second Edition Malden, MA Blackwell Science
33. Hahn GJ, Meeker WQ, Statistical Intervals 1991 New York, NY John Wiley & Sons
34. Corona A, Bertolini G, Lipman J, Antibiotic use and impact on outcome from bacteraemic critical illness: The BActeraemia Study in Intensive Care (BASIC). J Antimicrob Chemother 2010 65 1276 1285
35. Chowdhary G, Dutta S, Narang A, Randomized controlled trial of 7-day vs. 14-day antibiotics for neonatal sepsis. J Trop Pediatr 2006 52 427 432
36. Mermel LA, Allon M, Bouza E, Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009 49 1 45
37. Almuti K, Rimawi R, Spevack D, Effects of statins beyond lipid lowering: Potential for clinical benefits. Int J Cardiol 2006 109 7 15
38. Liu C, Bayer A, Cosgrove SE, Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: Executive summary. Clin Infect Dis 2011 52 285 292
39. Pylkkänen J, Vilska J, Koskimies O, The length of antimicrobial therapy in upper vs. Lower urinary tract infection of childhood. Acta Paediatr Scand 1981 70 885 888
40. Cheng CH, Tsau YK, Lin TY, Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. Pediatrics 2006 117 e84 e89